Healthy Skepticism Library item: 2263
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Perri M 3rd, Shinde S, Banavali R.
The past, present, and future of direct-to-consumer prescription drug advertising.
Clin Ther 2001 nov; 21:(10):1798-811
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRS-3YF46RW-J&_coverDate=10%2F31%2F1999&_alid=305967821&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=6242&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=18edbefe7a0a00f2fd03cf0fb73399c6
Keywords:
Department of Clinical and Administrative Sciences, College of Pharmacy, University of Georgia, Athens 30602, USA.
Since the first experiences with direct-to-consumer (DTC) prescription drug advertising in the early 1980s, pharmaceutical marketers, government regulators, researchers, health practitioners, and consumers have been both perplexed and intrigued by this practice. As experience with DTC advertising has expanded, so has knowledge and understanding of its risks and rewards. This article discusses important issues in DTC advertising, such as the effects it may have on the patient-practitioner relationship, the diffusion and adoption of new drugs, prices, and competition. It also discusses the future of DTC advertising.
MeSH Terms:
Advertising*
Drug Industry*
Humans
Legislation, Drug
Patient Compliance
Physician-Patient Relations
